Clinical Trials Logo

Filter by:
NCT ID: NCT05970289 Active, not recruiting - Clinical trials for Chronic Hepatitis B Virus Infection

Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients

Start date: August 22, 2023
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy and safety of PEG-IFNα alone or in combination with different dose levels of BRII-835 (VIR-2218) in participants with chronic hepatitis B virus (HBV) infection.

NCT ID: NCT05964582 Active, not recruiting - Clinical trials for Respiratory Syncytial Virus Infections

Prospective Surveillance of Respiratory Syncytial Virus Disease in Infants and Toddlers

Start date: July 11, 2023
Phase:
Study type: Observational

The study is a multi-center, multi-national, prospective surveillance study in which the study participants will not receive a study vaccine but will provide a baseline blood sample and be followed for acute respiratory disease during 6 months. The 6-month follow-up will occur for the most part during the Respiratory Syncytial Virus(RSV) season (based on enrollment timing and as per feasibility). A maximum of 1000 children from 6 to < 22 months of age are planned to be enrolled in 5 to 10 countries, 1 to 2 sites per country, targeting approximately 100 participants per country. The purpose of the study is to assess the seroprevalence and incidence of RSV disease during the study period in the targeted countries and sites for a Phase III vaccine study.

NCT ID: NCT05895955 Active, not recruiting - Influenza Clinical Trials

Safety and Immunogenicity of GPO Seasonal Tetravalent Inactivated Split Virion Influenza Vaccine in Healthy Thais

Start date: November 4, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The study is aim to evaluate the safety and immunogenicity of one dose TetraFluvac TF vaccine (15 μg HA per strain per dose) of the GPO seasonal quadrivalent inactivated split virion influenza vaccine in healthy adults aged 18 years and above over 90 days post-injection.

NCT ID: NCT05827029 Active, not recruiting - Obesity Clinical Trials

Gastric Volume After Ingestion of Carbohydrate Drink vs Water in Obese Volunteers

Start date: April 1, 2023
Phase: N/A
Study type: Interventional

This randomized crossover study compares gastric residual volume after ingestion of carbohydrate drinks and water in obese volunteers. The main question[s] it aims to answer are: - Is it safe for obese patients to shorten their fasting by allowing preoperative drinks? - How long is the gastric emptying time in obese patients? Participants also will be evaluated the level of thirst/hungry and blood sugar.

NCT ID: NCT05809934 Active, not recruiting - Clinical trials for Nonalcoholic Steatohepatitis

A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

FORTUNA
Start date: March 15, 2023
Phase: Phase 2
Study type: Interventional

A Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 given by subcutaneous injection in adult participants with non-cirrhotic non-alcoholic steatohepatitis with fibrosis and who are carriers of the PNPLA3 148M Risk Allele

NCT ID: NCT05777148 Active, not recruiting - Clinical trials for End Stage Renal Disease

Comparison of Efficacy in Removal of Advanced Glycation End Products (AGEs) Between Super High-flux Hemodialysis and Postdilution Online Hemodiafiltration: A Single-center, Prospective, Open-label, Crossover Randomized Controlled Trial

Start date: April 4, 2022
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to compare efficacy in advanced glycation end products removal between Super high-flux Hemodialysis and high-volume post-dilution online hemodiafiltration. The main question it aims to answer are - Efficacy : endothelial dysfunction biomarker (AGEs) in super high-flux hemodialysis compared to online HDF - Safety profile : Dialysate albumin loss, Intradialytic complication Participants will be asked to randomized in 2 groups : Super high-flux HD or post dilution ol-HDF Researchers will compare SHF-HD and ol-HDF to see whether SHF-HD could remove AGEs better than ol-HDF

NCT ID: NCT05758415 Active, not recruiting - Clinical trials for Rotator Cuff Tendinopathy

Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy

Start date: August 2, 2023
Phase: Phase 3
Study type: Interventional

The purpose of the present study is to assess the efficacy of secukinumab 300 mg s.c. (subcutaneous) compared to placebo, each in combination with standard of care, in improving signs, symptoms and physical function in participants with moderate to severe rotator cuff tendinopathy (RCT), using a randomized, double-blind, placebo controlled, parallel group design to minimize bias.

NCT ID: NCT05724589 Active, not recruiting - Aging Clinical Trials

The Effectiveness of Epidermal Growth Factor Serum in Improve Facial Skin Hydration, Elasticity, Pigmentation, and Wrinkles.

Start date: January 30, 2023
Phase: N/A
Study type: Interventional

EGF is a polypeptide that promotes cell differentiation and collagen production while decreasing melanin production. This study is designed to study its effectiveness in improving the texture and appearance of facial skin after daily topical application. We hypothesized that EGF would improve facial skin hydration, elasticity, pigmentation, and wrinkles.

NCT ID: NCT05722015 Active, not recruiting - Clinical trials for Metastatic Non-small Cell Lung Cancer

A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)

Start date: February 14, 2023
Phase: Phase 3
Study type: Interventional

This study is to assess the pharmacokinetics (PK) and safety of SC MK-3475A vs intravenous (IV) pembrolizumab, administered with chemotherapy in first line treatment of adult participants with metastatic non-small cell lung cancer. The primary hypotheses of this study are MK-3475A subcutaneous (SC) is noninferior to pembrolizumab IV with respect to PK parameters.

NCT ID: NCT05717907 Active, not recruiting - Clinical trials for Intubation Complication

Suction Catheter as a Guide for Nasotracheal Intubation Under General Anesthesia

Start date: September 5, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial to study the efficacy of suction catheter guided technique and conventional technique during nasotracheal intubation. The main question are - How effective of the use of a suction catheter guided ETT in reducing bleeding during nasotracheal intubation? - Does the use of a suction catheter guided ETT can improve its navigability through the nasal passage and reduce nasal passage time?